AGENERASE
LOE ApproachingNDAORALSOLUTION
Approved
Apr 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AGENERASE is an oral solution small-molecule drug approved by GSK in 1999. The specific mechanism of action and indications are not documented in available data, limiting clinical characterization. This product represents a mature asset approaching loss of exclusivity.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), suggesting limited team expansion and focus on lifecycle management and erosion mitigation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
AGENERASE offers limited career growth due to zero linked job openings and approaching loss of exclusivity. Roles available are primarily defensive, focused on maximizing remaining revenue and managing competitive decline rather than building new capabilities.
Brand ManagerCommercial Operations Analyst
Worked on AGENERASE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.